FDA Approves New Self-Collection HPV Tests for Cervical Cancer Screening

Innovative alternatives to traditional Pap smears aim to improve accessibility and comfort in healthcare settings.

Roche and BD have received FDA approval for HPV self-collection kits to be used in medical facilities.
These tests allow patients to collect their own samples, bypassing the need for a speculum exam.
Experts highlight that self-collection can reduce barriers and expand access to cervical cancer screening.
The tests are expected to be available in healthcare settings starting in September and later this fall.
While promising, insurance coverage for these new tests remains uncertain.